A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

NCT05030324 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

255

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza
Viral Respiratory Infection
Acute Viral Upper Respiratory Infections

Interventions

DRUG: XC221 100 mg
DRUG: XC221 200 mg
DRUG: Placebo

Sponsor

Valenta Pharm JSC